Arcellx, Inc. ACLX
We take great care to ensure that the data presented and summarized in this overview for Arcellx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACLX
View all-
Perceptive Advisors LLC New York, NY3.93MShares$214 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$208 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$204 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$167 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$128 Million54.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.23MShares$121 Million0.0% of portfolio
-
State Street Corp Boston, MA1.89MShares$103 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.78MShares$96.8 Million7.13% of portfolio
-
Suvretta Capital Management, LLC New York, NY1.56MShares$85 Million4.65% of portfolio
-
Janus Henderson Group PLC London, X01.52MShares$82.8 Million0.06% of portfolio
Latest Institutional Activity in ACLX
Top Purchases
Top Sells
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at ACLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-34.45%
|
$1,100,000
$55.58 P/Share
|
|
Jun 12
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.36%
|
$200,000
$10.64 P/Share
|
|
May 24
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,121
-37.98%
|
$606,050
$50.71 P/Share
|
|
May 23
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,428
+41.27%
|
-
|
|
May 01
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
18,168
-21.21%
|
$944,736
$52.16 P/Share
|
|
May 01
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,168
+40.13%
|
$109,008
$6.28 P/Share
|
|
Apr 16
2024
|
Olivia C Ware |
SELL
Open market or private sale
|
Direct |
9,402
-86.11%
|
$517,110
$55.7 P/Share
|
|
Apr 16
2024
|
Olivia C Ware |
BUY
Exercise of conversion of derivative security
|
Direct |
9,402
+50.0%
|
$65,814
$7.61 P/Share
|
|
Apr 01
2024
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
23,086
-8.99%
|
$1,546,762
$67.56 P/Share
|
|
Mar 26
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,450
-14.58%
|
$376,050
$69.37 P/Share
|
|
Mar 26
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,450
+27.47%
|
$32,700
$6.28 P/Share
|
|
Mar 22
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
41,365
-31.24%
|
$2,895,550
$70.83 P/Share
|
|
Mar 22
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+28.45%
|
$120,000
$6.28 P/Share
|
|
Mar 21
2024
|
Jill Carroll |
SELL
Open market or private sale
|
Indirect |
504,263
-25.42%
|
$35,298,410
$70.55 P/Share
|
|
Mar 18
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,825
-23.74%
|
$470,925
$69.38 P/Share
|
|
Mar 15
2024
|
Olivia C Ware |
SELL
Open market or private sale
|
Direct |
9,000
-58.04%
|
$630,000
$70.26 P/Share
|
|
Mar 15
2024
|
Olivia C Ware |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+50.0%
|
$63,000
$7.61 P/Share
|
|
Feb 12
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,967
-8.92%
|
$189,888
$64.46 P/Share
|
|
Feb 12
2024
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct |
11,169
-10.79%
|
$714,816
$64.46 P/Share
|
|
Feb 09
2024
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,688
-9.98%
|
$232,344
$63.4 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 393K shares |
|---|
| Open market or private sale | 1.37M shares |
|---|